Search
Results
showing 1-10 of 2293
Global Health Watch: Exec Order Changes Childhood Vaccine Recs, $2B in Faith-based Aid, NIH Restricts Policy Rx
August 2026
This week, the US Administration announced $2 billion in global health funding for faith-based organizations; US Congress intensified oversight of PEPFAR and the bilateral global health agreements; the NIH moves to restrict policy-focused research; and – perhaps most alarmingly – the US President issued an executive order rewriting longstanding, evidence-based childhood vaccine recommendations.
INCLUSION Global Study Details
August 2026
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries.
Accelerating policy approval and uptake of the dual prevention pill in Zambia through early stakeholder engagement
August 2026
The Dual Prevention Pill (DPP), a combination of PrEP and combined oral contraception (COC), offers a novel, female-controlled option for HIV and unintended pregnancy prevention. This article in AIDS Care, authored by AVAC Fellow Rhoda Msiska, AVAC staff members Kate Segal and Cindra Feuer, and Newton Donkola, demonstrates how early, multisectoral stakeholder engagement could accelerate DPP approval and adoption in Zambia.
Global Health Watch: Fauci in Contempt + New NIAID Director, Senate Blocks OMB’s Grant Proposal, New CDC Director, AIDS 2026 Highlights
August 2026
This week, the US Senate Committee on Homeland Security & Governmental Affairs voted along party lines to hold Anthony Fauci in contempt of Congress for his refusal to answer questions during last week’s hearing on the COVID-19 response testimony – while it was rumored that Steven Quay, a lab-leak proponent, is in line for Fauci’s old job. At the same time, the US Senate Appropriations Committee did step up to stop the White House OMB’s politicization of federal research grants. There’s also – finally – a new leader of the US Centers for Disease Control and Prevention (CDC). And the HIV/AIDS community is unpacking major themes emerging from the AIDS 2026 conference.
AVAC Says Stop the Waste, Fraud and Abuse in the Persecution of Tony Fauci
August 2026
AVAC vehemently opposes the decision by the U.S. Senate Homeland Security and Governmental Affairs Committee to hold Dr. Anthony Fauci in contempt for his refusal to answer questions during last week’s hearing on the COVID-19 response. Certain members of the committee have made clear their intentions to pin the shortcomings of the U.S. response to COVID-19 on others by blaming and dragging renowned government scientists and public health practitioners such as Dr. Fauci through politicized proceedings without any evidence and using conspiratorial conjecture.
Long-Acting PrEP Generic License Coverage
August 2026
This map shows country coverage under current voluntary licensing agreements for generic versions of three long-acting PrEP products: alimatravir (ALI), cabotegravir (CAB) and lenacapavir (LEN). The graphic reflects publicly announced licenses and does not indicate product registration, availability or access within countries. For more information, visit the PrEPWatch Long-Acting PrEP Status page.
Beyond AIDS 2026: AVAC’s Top 10
August 2026
Following the AIDS 2026 conference in Rio de Janeiro, our team compiled a list of AVAC’s top 10 takeaways. These topics sparked discussions and ideas among our team and AVAC’s larger partner network, and will carry our work well into the future.
AIDS 2026: Rising Above to Meet the Moment
August 2026
Following AIDS 2026 in Rio de Janeiro, AVAC’s Executive Director Mitchell Warren reflects on a week of conversations, sessions, and new data. As he puts it, Rio was a reminder that science has never been stronger, communities have never been more ready, and the need has never been more urgent. Ending HIV is no longer limited by what we know, it is limited only by the courage to act.
Global Health Watch: Fauci Testifies as AIDS 2026 Wraps Up, Gavi Receives its Funding & New Policy Restricts Gain-of-Function Research
July 2026
Scientists and advocates gathered in Rio for the 26th International AIDS Conference (AIDS 2026) this week to discuss the future of the HIV response, just as former NIAID Director Anthony Fauci appeared before a hostile Senate Committee on Homeland Security & Governmental Affairs, reminding us that the greatest barriers to ending HIV are increasingly political, not scientific. In addition, this week’s issue covers the US Administration’s use of vaccine funding as leverage in negotiations with Gavi and a new policy restricting gain-of-function research.
Science, Systems, and Communities: Turning Progress into Impact
July 2026
As the AIDS 2026 conference enters its second half, one message has emerged above all others: the barriers to ending HIV are no longer primarily scientific; they are political. Read on for AVAC’s highlights so far at the conference.
showing 1-10 of 2293